Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terproline is a dermocosmetic product line developed by General Topics under the Synchroline brand, specifically formulated to improve skin elasticity and firmness. The product line utilizes a synergistic combination of active ingredients, including triterpenes from *Centella asiatica* (asiaticoside, madecassic acid, and asiatic acid), acetylglucosamine, and proline linoleate. These components are designed to stimulate the biosynthesis of essential dermal matrix components such as collagen, elastin, and hyaluronic acid. Terproline is primarily used to prevent and treat stretch marks (striae distensae), address skin sagging, and support skin recovery following surgical or aesthetic procedures like liposuction, blepharoplasty, or chemical peels. It is available in various topical formulations, including creams for the face and body, as well as specialized gels for the periocular and perioral areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Terproline.